UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 31, 2023
NASCENT BIOTECH, INC. |
(Exact name of registrant as specified in its charter) |
Nevada |
| 000-55299 |
| 46-5001940 |
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
623 17th Street Suite 4 Vero Beach FL. |
| 32970 |
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code (612) 961-5656
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 OTHER EVENTS
On August 31, 2023, NASCENT BIOTECH INC. (the “Company”) entered into an agreement with YAII PN, LTD (“YAII”) for the repayment of $400,000 of the Company’s convertible debentures held by YAII. Under the terms of this agreement, the Company paid $50,000 on August 24, 2023 and will pay $50,000 on or before September 30, 2023, $50,000 on or before October 31, 2023 and $250,000 on or before December 31, 2023.
As part of the agreement, YAII will not convert any of the debentures to common stock and will forgive the interest if the terms are met.
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NASCENT BIOTECH, INC. |
|
|
|
/s/ Sean Carrick |
|
Sean Carrick |
|
President |
|
|
|
Date: September 6, 2023 |
|
3 |
